Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib trial of SOL 784

Next Previous
X
Search
Trial Profile

A phase Ib trial of SOL 784

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SOL 784 (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Sep 2021 New trial record
    • 02 Sep 2021 According to a Sentinel Oncology media release, McQuade Center for Strategic Research and Development, LLC (MSRD) has entered an agreement with Sentinel Oncology. Under the terms of the agreement, MSRD and Sentinel will collaborate to support this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top